ClinicalTrials.gg
CompletedNCT00625443Updated Mar 16, 2018Results posted

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

A Phase 2 interventional study of Blinded (placebo) and Open Label (Avatrombopag tablets) in Idiopathic Thrombocytopenic Purpura, sponsored by Eisai Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-16.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
8th of 16
53 · median 53
Started
2007
with 1 other
Phase 2
4 of 16
2 open now
Registered
2nd of 16
by date
Lead sponsor
7 of 16
Eisai Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 8th largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 2, and was the 2nd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003 (NCT00441090).

Read the detailed description

Participants eligible to enroll into this rollover protocol will begin study treatment within 2-5 days of their Day 28 study termination visit in Protocol 501-CL-003 (NCT00441090). Participants who met the primary efficacy response criterion in Protocol 501-CL-003 will continue receiving the same study treatment to which they were assigned in the previous protocol in a double-blinded manner, these being one of the following 5 treatments:

  • avatrombopag 2.5 mg daily
  • avatrombopag 5 mg daily
  • avatrombopag 10 mg daily
  • avatrombopag 20 mg daily
  • placebo

Participants who did not meet the primary efficacy response criterion in Protocol 501-CL-003 who otherwise meet the eligibility criteria for this rollover protocol will be offered open label avatrombopag 10 mg daily.

This is a parallel group, rollover study.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • Idiopathic Thrombocytopenic Purpura
  • ITP
  • Chronic Idiopathic Thrombocytopenic Purpura
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who completed 28 days of study treatment in Protocol 501-CL-003.
  2. No significant safety or tolerability concerns from the patient's participation of Protocol 501-CL-003 as determined by the Investigator.
  3. Received medical monitor approval for enrollment into this study.
  4. Patients receiving maintenance may be enrolled, as long as the corticosteroids have been administered at a stable dose and the Investigator does not foresee the need to change the steroid dose during study participation. Patients should remain on this stable corticosteroid dose during study participation.
  5. Women of must have a negative serum pregnancy test at the Day 28 assessment in Protocol 501-CL-003. (Childbearing potential is defined as any woman who has not been surgically sterilized and is pre-menopausal or peri-menopausal i.e., any menstrual flow within 12 months of Screening Visit A for Protocol 501-CL-003).
  6. Women of child-bearing potential must agree to practice a medically approved form of (one of the following must be used: condoms (male or female) with a spermicidal agent, diaphragm or cervical cap with a spermicidal agent, IUD,hormonal contraception, abstinence).
  7. Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant and/or lactating.
  2. Use of the following drugs or treatments:

    • Rituximab
    • Azathioprine, Cyclosporine A, or other therapy
    • Aspirin, Aspirin-containing compounds, Salicylates,Anticoagulants, Non-steroidal anti-inflammatory drugs(NSAIDs)(including Cyclooxygenase-2 [COX-2] specific NSAIDs), clopidogrel; ticlopidine; and any drugs that affect function.
    • Danazol
    • Rh0(D) immune globulin (WinRho®) or intravenous immunoglobulin (IVIG).
  3. Inability to comply with protocol requirements or give , as determined by the Investigator.

For more information regarding inclusion/exclusion criteria, please see record for AKR 501-CL-003 Protocol.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Placebo (double-blind)

    Drug: Blinded (placebo)

  • Experimental
    Avatrombopag tablets (open-label)

    Drug: Open Label (Avatrombopag tablets)

  • Experimental
    Avatrombopag tablets (double-blind)

    Drug: Blinded (Avatrombopoag tablets)

Interventions

  • DrugBlinded (placebo)

    Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack) Duration - 6 months

  • Dose 10 mg Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack) Duration - 6 months

    Also known as: AKR-501, E5501, YM477

  • Dose: 2.5, 5, 10, or 20 mg Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack) Duration - 6 months

    Also known as: AKR-501, E5501, YM477

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of study drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. Related AEs included those whose relationship was categorized as possible or probably by the investigator. Dose interruption includes dose decreased, dose previously stopped, permanently stopped, or temporarily stopped. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).

    Time frame: Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.

  2. Incidence of Severe (Grade 3 or 4) TEAEs

    A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).

    Time frame: Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.

  3. Incidence of Drug-Related TEAEs

    Drug-related TEAEs included those whose relationship was categorized as possible or probably by the investigator. A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).

    Time frame: Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.

Secondary outcomes

  1. Median Platelet Counts at Selected Analysis Timepoints

    Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

    Time frame: Day 1, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4

  2. Percentage of Participants Who Achieved a Platelet Count of 100,000/mm^3 or Higher by Response Status and Selected Study Visit

    Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

    Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4

  3. Percentage of Participants Who Maintained a Platelet Count of 100,000/mm^3 or Higher by Response Status

    Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

    Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4

  4. Percentage of Participants Who Achieved Response-Level Platelet Count by Selected Study Visit

    Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

    Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4

  5. Percentage of Participants Who Maintained Response-Level Platelet Count

    Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

    Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4

  6. Percentage of Participants Who Achieved a Durable, Transient, or Overall Platelet Response

    Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

    Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4

  7. Number of Participants With Changes in Concomitant Steroid Use

    A participant who used steroids at study entry was considered to have permanently discontinued steroid use if they had no steroid use during the last 8 weeks of the study Treatment Period. A participant who used steroids at study entry was considered to have decreased concomitant steroid medication by at least 50% if they permanently discontinued steroids, or in no dose of steroid was higher than 50% of their baseline steroid dose during the last 8 weeks of the study Treatment Period.

    Time frame: Day 1 through last 8 weeks of the Treatment Period

07

Results

Posted Mar 16, 2018

Participant flow

Participant flow — Overall Study
MilestoneLower 1/3 Avatromboopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose Group
Started122615
Completed101510
Not completed2115
Withdrew: Adverse event140
Withdrew: Non-compliance with protocol010
Withdrew: Platelet count increase >=500,000/mm3100
Withdrew: Withdrawal by subject012
Withdrew: Physician decision042
Withdrew: Other011

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of study drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. Related AEs included those whose relationship was categorized as possible or probably by the investigator. Dose interruption includes dose decreased, dose previously stopped, permanently stopped, or temporarily stopped. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).

Time frame:
Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsLower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose Group
TEAEs122414
Severe (Grade 3-4) TEAEs476
Treatment-related TEAEs5157
Serious TEAEs243
Serious treatment-related TEAEs120
Withdrawal of study drug due to TEAE240
Dose interruption due to TEAE232
Deaths000
PrimaryIncidence of Severe (Grade 3 or 4) TEAEs

A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).

Time frame:
Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.
Reported as:
Count of participants · Participants
Incidence of Severe (Grade 3 or 4) TEAEs
ParticipantsLower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose Group
Thrombocytopenia124
Splenomegaly001
Haemorrhagic diathesis010
Idiopathic thrombocytopenic purpura100
Leukocytosis010
Mitral valve incompetence001
Diarrhoea001
Vomiting001
Fatigue200
Oedema peripheral100
Asthenia100
Chest pain001
Pyrexia001
Platelet count increased210
Platelet count decreased020
Alanine aminotransferase increased001
Aspartate aminotransferase increased001
Hyperuricaemia100
Back pain100
Dizziness100
Hypoaesthesia001
Cerebrovascular accident001
Haemorrhage intercranial010
Epistaxis100
Hypotension100
Pelvic venous thrombosis010
PrimaryIncidence of Drug-Related TEAEs

Drug-related TEAEs included those whose relationship was categorized as possible or probably by the investigator. A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).

Time frame:
Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.
Reported as:
Count of participants · Participants
Incidence of Drug-Related TEAEs
ParticipantsLower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose Group
Thrombocytopenia120
Splenomegaly011
Anaemia010
Leukocytosis010
Vision blurred010
Visual disturbance010
Nausea002
Abdominal pain upper001
Diarrhoea010
Vomiting001
Fatigue241
Oedema peripheral010
Platelet count increased220
Platelet count decreased020
Alanine aminotransferase increased010
Hyperlipidaemia210
Decreased appetite001
Arthralgia011
Back pain002
Pain in extremity020
Arthropathy010
Muscular weakness001
Headache211
Dizziness111
Hypoaesthesia001
Mood swings100
Haematuria010
Menorrhagia100
Dyspnoea110
Epistaxis101
Nasal congestion001
Rash010
SecondaryMedian Platelet Counts at Selected Analysis Timepoints

Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

Time frame:
Day 1, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Reported as:
Median · Platelets x 1000/mm^3
Median Platelet Counts at Selected Analysis Timepoints
Platelets x 1000/mm^3RespondersNonresponders
Day 155.0 (7 to 316)23.5 (8 to 240)
Week 2126.0 (39 to 855)54.5 (5 to 1207)
Week 4113.0 (8 to 489)38.0 (6 to 383)
Week 6104.0 (18 to 880)47.0 (10 to 731)
Week 8137.0 (13 to 571)45.5 (3 to 263)
Week 1085.5 (32 to 179)72.0 (9 to 702)
Week 1288.0 (4 to 293)72.0 (2 to 557)
Week 1484.0 (29 to 296)77.5 (9 to 368)
Week 16143.0 (45 to 395)46.0 (3 to 273)
Week 18119.0 (28 to 303)78.0 (17 to 382)
Week 2092.0 (39 to 322)68.0 (18 to 481)
Week 22109.0 (26 to 354)78.5 (14 to 502)
Week 24154.0 (28 to 335)66.0 (19 to 368)
Follow-up Week 159.0 (8 to 495)40.0 (23 to 365)
Follow-up Week 225.0 (6 to 86)22.0 (8 to 426)
Follow-up Week 327.0 (3 to 380)36.0 (14 to 791)
Follow-up Week 435.0 (15 to 331)28.0 (1 to 881)
SecondaryPercentage of Participants Who Achieved a Platelet Count of 100,000/mm^3 or Higher by Response Status and Selected Study Visit

Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

Time frame:
Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Platelet Count of 100,000/mm^3 or Higher by Response Status and Selected Study Visit
Percentage of participantsRespondersNonresponders
Week 259.125.0
Week 458.318.5
Week 852.415.4
Week 1242.935.0
Week 1663.617.6
Week 2040.025.0
Week 2471.435.3
Follow up Week 118.227.3
Follow up Week 2033.3
Follow up Week 325.011.1
Follow up Week 423.113.3
SecondaryPercentage of Participants Who Maintained a Platelet Count of 100,000/mm^3 or Higher by Response Status

Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

Time frame:
Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Maintained a Platelet Count of 100,000/mm^3 or Higher by Response Status
Percentage of participantsRespondersNonresponders
Percentage of Participants Who Maintained a Platelet Count of 100,000/mm^3 or Higher by Response Status32.00
SecondaryPercentage of Participants Who Achieved Response-Level Platelet Count by Selected Study Visit

Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

Time frame:
Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Response-Level Platelet Count by Selected Study Visit
Percentage of participantsRespondersNonresponders
Week 286.453.6
Week 479.244.4
Week 890.546.2
Week 1285.765.0
Week 1681.847.1
Week 2090.066.7
Week 2481.070.6
Follow up Week 154.545.5
Follow up Week 210.033.3
Follow up Week 341.744.4
Follow up Week 438.533.3
SecondaryPercentage of Participants Who Maintained Response-Level Platelet Count

Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

Time frame:
Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Maintained Response-Level Platelet Count
Percentage of participantsRespondersNonresponders
Percentage of Participants Who Maintained Response-Level Platelet Count56.00
SecondaryPercentage of Participants Who Achieved a Durable, Transient, or Overall Platelet Response

Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.

Time frame:
Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Durable, Transient, or Overall Platelet Response
Percentage of participantsRespondersNonresponders
Durable Platelet Response72.035.7
Transient Platelet Response16.028.6
Overall Response88.064.3
SecondaryNumber of Participants With Changes in Concomitant Steroid Use

A participant who used steroids at study entry was considered to have permanently discontinued steroid use if they had no steroid use during the last 8 weeks of the study Treatment Period. A participant who used steroids at study entry was considered to have decreased concomitant steroid medication by at least 50% if they permanently discontinued steroids, or in no dose of steroid was higher than 50% of their baseline steroid dose during the last 8 weeks of the study Treatment Period.

Time frame:
Day 1 through last 8 weeks of the Treatment Period
Reported as:
Number · Number of participants
Number of Participants With Changes in Concomitant Steroid Use
Number of participantsRespondersNonresponders
Permanently Discontinued44
Decreased by greater than or equal to 50%76

Adverse events

Collected over Approximately 7 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lower 1/3 Avatrombopag Dose Group0/12 (0%)2/12 (16.7%)12/12 (100%)
Middle 1/3 Avatrombopag Dose Group0/26 (0%)4/26 (15.4%)24/26 (92.3%)
Upper 1/3 Avatrombopag Dose Group0/15 (0%)3/15 (20%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventLower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose Group
ThrombocytopeniaBlood and lymphatic system disorders1/121/262/15
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders1/120/260/15
Back painMusculoskeletal and connective tissue disorders1/120/260/15
HypotensionVascular disorders1/120/260/15
Mitral valve incompetenceCardiac disorders0/120/261/15
VomitingGastrointestinal disorders0/121/261/15
DiarrhoeaGastrointestinal disorders0/120/261/15
Chest painGeneral disorders0/120/261/15
PyrexiaGeneral disorders0/120/261/15
Cerebrovascular accidentNervous system disorders0/120/261/15
Most frequent other events
Showing 10 of 30
Most frequent other events
EventLower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose Group
FatigueGeneral disorders5/124/264/15
HeadacheNervous system disorders2/127/263/15
ThrombocytopeniaBlood and lymphatic system disorders1/123/264/15
PetechiaeSkin and subcutaneous tissue disorders3/121/262/15
ContusionInjury, poisoning and procedural complications3/123/263/15
Gingival bleedingGastrointestinal disorders1/123/263/15
NauseaGastrointestinal disorders0/121/263/15
Oedema peripheralGeneral disorders1/122/263/15
EpistaxisRespiratory, thoracic and mediastinal disorders2/124/263/15
CoughRespiratory, thoracic and mediastinal disorders1/121/263/15

Baseline characteristics

Full analysis set (FAS) included all participants who completed 501-CL-003 and received study drug in 501-CL-004, except baseline values and ITP-directed medications taken during the 2-week period before the first dose of avatrombopag in 501-CL-004. Data was summarized using the observed case (OC) method.

Age, Continuous
Age, Continuous(Years)Lower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose GroupTotal
Geometric mean44.7 ± 21.0952.5 ± 18.4450.4 ± 15.6550.1 ± 18.25
Sex: Female, Male
Sex: Female, Male(Participants)Lower 1/3 Avatrombopag Dose GroupMiddle 1/3 Avatrombopag Dose GroupUpper 1/3 Avatrombopag Dose GroupTotal
Female7201138
Male56415
08

Study locations

12 sites
  • Pacific Cancer Medical Center, Inc
    Anaheim, California 92801, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Davis, Posteraro and Wasser, MDs, LLP
    Manchester, Connecticut 06105, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology
    Chicago, Illinois 60612, United States
  • Cancer Care Center, Inc.
    New Albany, Indiana 47150, United States
  • Capitol Comprehensive Cancer Care Clinic
    Jefferson City, Missouri 65109, United States
  • Kansas City Cancer Center, LLC
    Kansas City, Missouri 64131, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • New York Presbyterian Hospital, Weill Medical College of Cornell University
    New York, New York 10032, United States
  • Emerywood Oncology and Hematology
    High Point, North Carolina 27262, United States
  • Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center
    Columbus, Ohio 43219, United States
09

References and documents

Publications

  • Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. doi: 10.1182/blood-2013-07-514398. Epub 2014 May 6. PubMed 24802775 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jun 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2018, 8 years 9 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2008
First posted
Feb 28, 2008
Start
May 2007
Primary completionActual
Jun 2009
CompletionActual
Oct 2009
Results delay requested
May 21, 2013
Results first posted
Mar 16, 2018
Last update
Mar 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00625443
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 28, 2008
Start date
May 2007
Primary completion
Jun 2009
Completion
Oct 2009
Results posted
Mar 16, 2018
Last update
Mar 16, 2018

Study contacts

Pei-Ran Ho, MD
study director · Eisai Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion